Healio

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...
Nasdaq

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Benzinga.com

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections

Ocrevus Zunovo is the first and only biannual professional-administered ~10 min SC injection approved for both forms of multiple sclerosis. The subcutaneous formulation of Tecentriq received its first ...
Nasdaq

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...
The American Journal of Managed Care

Subcutaneous Ofatumumab Shows Reduced Injection Reactions in Multiple Sclerosis

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...
Morningstar

ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...
Yahoo

US FDA declines to approve Viatris's injection for multiple sclerosis

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of ...
The American Journal of Managed Care

FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe ...
Multiple Sclerosis News Today

MS patients value empathy as a top priority in their healthcare

A study reveals that MS patients value person-centered care and empathy as much as their doctor's skills or medical training.
Washington Examiner

Correction: FDA-Multiple Sclerosis Drug story

WASHINGTON (AP) — In a story March 27 about a new multiple sclerosis drug, The Associated Press reported erroneously that Novartis’ drug Gilenya was launched in March 2011. The drug was launched in ...
Reuters

US FDA declines to approve Viatris's injection for multiple sclerosis

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...